Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer | AVESİS

Istanbul University Research Information System

Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer

Copy For Citation

Kato K., Shah M. A., Enzinger P. C., Bennouna J., Shen L., Adenis A., ...More

43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29

Publication Type: Conference Paper / Summary Text
Volume: 29
City: Munich
Country: Germany
Istanbul University Affiliated: Yes